Nutex Health

NUTX · NASDAQ

$198.99+$7.74 (+4.05%)TodayMarket closed · Oct 20, 7:40 PM ET

Prev close $191.25

NUTX analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $293.96 (+47.7% upside)

Low: $202.00
Now: $198.99
High: $341.25

Upgrades and downgrades

The latest rating actions, newest first

NUTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Freedom Capital Markets	Sep 25, 2026	Maintains	Buy	$280.00 → $306.00	64%
B. Riley Securities	Sep 4, 2026	Maintains	Buy	$290.00 → $325.00	37%
Lake Street	Aug 11, 2026	Maintains	Buy	$235.00 → $310.00	41%
B. Riley Securities	Jun 26, 2026	Initiates	Buy	$290.00	53%
Lake Street	Jun 2, 2026	Initiates	Buy	$235.00	41%

The case for and against

Updated Oct 18, 2026

Bull case

Nutex Health is attractive fundamentally because its micro-hospital model is capital-efficient and scalable, with a typical facility reaching breakeven at about 15 visits per day, generating high-40s/low-50s gross margins and low-30s EBITDA margins, while mature units average roughly $35M of revenue and $10M of EBITDA. The investment case is strengthened by improving reimbursement mechanics: the Fifth Circuit’s August 11 ruling and lower IDR fees should reduce arbitrations, lift first-pass payments, and support collections that already exceed 80% of award value on wins. It also has a strong growth flywheel, with 10+ openings planned through 2028, 28 micro-hospitals already operating, and physician alignment driving 90–95%+ retention and recurring patient volume.

Bear case

Nutex Health is facing a fundamentally fragile earnings profile because its hospital division depends on a tight labor market, volatile reimbursement, and the ability to keep volumes from migrating to lower-cost alternatives like telemedicine and retail clinics. Its exposure to the federal IDR process makes profitability structurally lumpy, while CMS rulemaking, tighter regulation, and litigation risk could compress awards and disrupt a model already sensitive to arbitration-derived reimbursement. Execution risk further clouds the outlook, as delays, cost overruns, or unfavorable sale-leaseback financing could slow capital recycling and pressure the balance sheet even after the $52.3M non-cash reduction in contract services in 2Q26.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.